Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Germany (DAX) (EWG) vs Invesco Ltd. (IVZ) Price & Performance

iShares MSCI Germany (DAX)Trade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

iShares MSCI Germany (DAX) vs Invesco Ltd. — how do they compare? iShares MSCI Germany (DAX) trades at $40.97 (market cap $1.42B), while Invesco Ltd. trades at $29.52 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 9.4× iShares MSCI Germany (DAX)'s market cap, and Invesco Ltd. pays a 2.86% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 54 Days and Invesco Ltd. for 77 Days on average.

EWGIVZ
Market Cap
$1.42B$13.28B
Volume
1,110,5733,698,033
Sector
Broad Market / FactorFinancials
52-Week High
$44.59$33.31
52-Week Low
$38.08$22.44
Typical Hold Time
54 Days77 Days
Enterprise Value
—$23.45B
Dividend Yield
—2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Germany (DAX)

EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.

Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.

Invesco Ltd.

Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.

The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWG
100% Buy0% Sell
Avg holding period · 54 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About iShares MSCI Germany (DAX)

EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.

Read more on EWG →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →